EP3250199A4 - A pharmaceutical composition for treating gastrointestinal diseases - Google Patents

A pharmaceutical composition for treating gastrointestinal diseases Download PDF

Info

Publication number
EP3250199A4
EP3250199A4 EP16743704.5A EP16743704A EP3250199A4 EP 3250199 A4 EP3250199 A4 EP 3250199A4 EP 16743704 A EP16743704 A EP 16743704A EP 3250199 A4 EP3250199 A4 EP 3250199A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
gastrointestinal diseases
treating gastrointestinal
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16743704.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3250199A2 (en
Inventor
Young Ho Jo
Jun Woo Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3250199(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of EP3250199A2 publication Critical patent/EP3250199A2/en
Publication of EP3250199A4 publication Critical patent/EP3250199A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16743704.5A 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases Withdrawn EP3250199A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (ko) 2015-01-30 2015-10-22 위장질환 치료용 의약 조성물
PCT/KR2016/000935 WO2016122226A2 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Publications (2)

Publication Number Publication Date
EP3250199A2 EP3250199A2 (en) 2017-12-06
EP3250199A4 true EP3250199A4 (en) 2018-08-08

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16743704.5A Withdrawn EP3250199A4 (en) 2015-01-30 2016-01-28 A pharmaceutical composition for treating gastrointestinal diseases

Country Status (19)

Country Link
EP (1) EP3250199A4 (zh)
JP (1) JP6419347B2 (zh)
KR (2) KR101583452B1 (zh)
CN (1) CN107205947B (zh)
AR (1) AR105413A1 (zh)
CL (1) CL2017001680A1 (zh)
CO (1) CO2017006222A2 (zh)
EA (1) EA032385B9 (zh)
EC (1) ECSP17038599A (zh)
GE (1) GEP20196941B (zh)
MA (1) MA41432A (zh)
MX (1) MX2017007567A (zh)
MY (1) MY195824A (zh)
PE (1) PE20171340A1 (zh)
PH (1) PH12017550051A1 (zh)
SA (1) SA517382016B1 (zh)
TW (1) TWI635859B (zh)
UA (1) UA116517C2 (zh)
WO (1) WO2016122226A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (ko) 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759300A1 (en) * 1994-04-26 1997-02-26 Chugai Seiyaku Kabushiki Kaisha Molten granulated sucralfate preparation and process for producing the same
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
WO2010001930A1 (ja) * 2008-07-01 2010-01-07 ライオン株式会社 固形内服製剤
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81011T1 (de) * 1987-03-09 1992-10-15 Procter & Gamble Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (ko) * 1992-01-22 1997-04-23 주식회사 대웅제약 위장질환 치료용 의약 조성물
JPH0879097A (ja) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd 携帯無線機
KR970006083A (ko) 1995-07-06 1997-02-19 한승준 자동차용 카울부의 와이어 고정장치 취부구조
AU8354498A (en) * 1997-08-25 1999-03-16 Procter & Gamble Company, The Combined preparations for treating upper gastrointestinal tract distress
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
KR20110105223A (ko) * 2010-03-18 2011-09-26 일양약품주식회사 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0759300A1 (en) * 1994-04-26 1997-02-26 Chugai Seiyaku Kabushiki Kaisha Molten granulated sucralfate preparation and process for producing the same
WO2000078307A1 (en) * 1999-06-21 2000-12-28 Daewoong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
WO2010001930A1 (ja) * 2008-07-01 2010-01-07 ライオン株式会社 固形内服製剤
KR20140072673A (ko) * 2012-12-05 2014-06-13 (주)한국파비스제약 경구용 위장질환 치료를 위한 정제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAEWOONG PHARMACEUTICAL CO LTD: "Albis", XP002782150, Retrieved from the Internet <URL:http://www.daewoong.com/content/content.asp?FolderName=sub02&filename=sub02_0701_06> [retrieved on 20180618] *

Also Published As

Publication number Publication date
TWI635859B (zh) 2018-09-21
ECSP17038599A (es) 2017-09-29
KR20160094268A (ko) 2016-08-09
EP3250199A2 (en) 2017-12-06
MY195824A (en) 2023-02-22
SA517382016B1 (ar) 2021-03-18
AR105413A1 (es) 2017-10-04
CN107205947B (zh) 2020-05-22
KR101583452B1 (ko) 2016-01-11
WO2016122226A2 (en) 2016-08-04
JP2018503672A (ja) 2018-02-08
MX2017007567A (es) 2017-10-19
CN107205947A (zh) 2017-09-26
TW201639559A (zh) 2016-11-16
UA116517C2 (uk) 2018-03-26
PH12017550051A1 (en) 2018-01-29
EA032385B9 (ru) 2019-07-31
CL2017001680A1 (es) 2018-01-12
PE20171340A1 (es) 2017-09-13
CO2017006222A2 (es) 2017-09-20
EA201791458A1 (ru) 2017-11-30
EA032385B1 (ru) 2019-05-31
JP6419347B2 (ja) 2018-11-07
KR101583452B9 (ko) 2022-05-02
WO2016122226A3 (en) 2016-09-15
GEP20196941B (en) 2019-01-10
BR112017013857A2 (pt) 2018-02-27
MA41432A (fr) 2017-12-05

Similar Documents

Publication Publication Date Title
IL258213A (en) Pharmaceutical compounds
EP3263132A4 (en) Composition for treating il-6-related diseases
EP3319606A4 (en) PHARMACEUTICAL COMPOUND
EP3253382A4 (en) Pharmaceutical compositions for combination therapy
EP3104860A4 (en) Pharmaceutical compounds
EP3280421A4 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
GB201506658D0 (en) Pharmaceutical compounds
IL258246A (en) Pharmaceutical compounds
GB201504675D0 (en) Pharmaceutical compounds
GB201519352D0 (en) Pharmaceutical compounds
EP3368033A4 (en) THERAPEUTIC HONEY CANNABINOID COMPOSITION
GB201506660D0 (en) Pharmaceutical compounds
EP3302439A4 (en) Therapeutic composition
EP3349750A4 (en) PHARMACEUTICAL COMPOUND
GB201506933D0 (en) Pharmaceutical compounds
GB201502567D0 (en) Pharmaceutical compounds
EP3200826A4 (en) Pharmaceutical compositions for treating ebola virus disease
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
EP3141243A4 (en) Pharmaceutical composition
EP3272362A4 (en) Sustained-release pharmaceutical composition
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
EP3268046A4 (en) Conjugates for treating diseases
EP3100724A4 (en) Medicine for preventing ischemic diseases
EP3259254A4 (en) THERAPEUTIC COMPOUNDS
EP3524250A4 (en) PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170728

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20170728

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7024 20060101ALI20180622BHEP

Ipc: A61P 1/04 20060101ALI20180622BHEP

Ipc: A61K 9/28 20060101ALI20180622BHEP

Ipc: A61K 33/24 20060101ALI20180622BHEP

Ipc: A61K 31/341 20060101AFI20180622BHEP

Ipc: A61K 9/20 20060101ALI20180622BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180706

17Q First examination report despatched

Effective date: 20191122

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/16 20060101ALI20200507BHEP

Ipc: A61K 31/7024 20060101ALI20200507BHEP

Ipc: A61P 1/04 20060101ALI20200507BHEP

Ipc: A61K 9/20 20060101ALI20200507BHEP

Ipc: A61K 9/28 20060101ALI20200507BHEP

Ipc: A61K 31/341 20060101AFI20200507BHEP

Ipc: A61K 33/245 20190101ALI20200507BHEP

INTG Intention to grant announced

Effective date: 20200520

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201001